Moderna
This is the archived full research. Read the story
The maker of one of the two mRNA COVID vaccines, now betting its future on a cancer vaccine built from each patient's own tumour.
The scores
Growth1/4 ↑
Revenue fell from $19.3B in 2022 to $1.9B in 2025; Q3 2026 grew 29% and 2026 is guided up 15% to 25%.
Business quality2/4 ↑
The vaccines have no moat: sales fell 90%. Intismeran's Phase 3 is a real lead, but unproven in sales and half Merck's.
Financial position3/4 →
About $8.0B of cash and investments against $3.5B of debt due from 2031; liquidity above $9B covers a yearly gap near $1.5B.
Execution record2/4 ↑
Built the COVID vaccine at record speed, then missed revenue guides as demand fell; since then it cut costs and delivered the melanoma trial.
Per share capture2/4 →
Half of intismeran's profit goes to Merck, stock pay runs near a fifth of sales, and convertibles add about 14M shares.
Potential3/4 ↑
A positive Phase 3 in melanoma, three more Phase 3 trials enrolled in common cancers, and a 2027 launch planned; none has yet sold.
Risk profile2/4 →
Value rests on one medicine whose survival benefit is unproven, a rival's version failed in another cancer, and patent suits run both ways.
Valuation1/4 →
The price is about 552% of a value near $39 and above the bull case near $78 (C44), pricing success across several cancers (C45).
Evidence quality3/4 →
Filed statements, the trial result as presented to doctors, government cancer and vaccination data; the analyst day and the veterans study are secondhand.
If it works 0.2× · if it fails you keep about 12%.
The Verdict
We rate Moderna Unattractive. Its COVID vaccines, nearly all of its sales, keep shrinking and lose money, so the business is weak today. Its cancer vaccine, made with Merck, cut melanoma coming back by 42% in a large trial, a real result. But Merck keeps half of any profit, other cancers are untested, and a rival's version failed in bowel cancer. The price is about 552% of our value of about $39 a share and above even our optimistic case: it is stretched, paying for success across many cancers. As a bet it is priced: even a big win adds little.
The long caseIf a vaccine made from each patient's tumour keeps cancer from returning after surgery, it could be added to standard treatment in several common cancers.
How we weighed it
The price against our value
Against it
Price at 552% of our value
The price sits far above our value and above the bull case.
The business
Against it
Weak
The vaccines have no moat and the cancer vaccine has not yet sold.
Growth against what the price assumes
Cuts both ways
Sales grow again this year, but off a base a tenth of the peak, and the price assumes far more.
What could go wrong
Against it
Survival is unproven, a rival's version failed in another cancer, and Merck keeps half.
Against competitors
Against it
Priced at many times its filed rivals on sales.
How its group is behaving
Cuts both ways
It sits in none of our ranked groups; trial news moves it, not the market.
The latest news and report
In its favour
A positive late-stage trial, a strong quarter and a filing planned by year-end.
The evidence under this - 6 claims
The analysts' path may undercount intismeran in lung and other cancers; the bull case is the check, and the price is still nearly three times it.
A rival with a proven cancer platform could be worth this; the price could be pricing a platform beyond intismeran.
Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.
The company
Moderna's vaccines carry a set of genetic instructions that tell the body's own cells to make a harmless piece of a virus, so the immune system learns to recognise it. It sells shots against COVID, RSV and, since August 2026, flu to governments, pharmacies and health systems.
Its cancer vaccine works the same way, but it is made for one patient at a time from the mutations in that patient's removed tumour, and given with Merck's Keytruda to stop the cancer returning.
The evidence under this - 3 claims
Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.
A filing is not an approval, and an individualized medicine made for each patient has no precedent at this scale.
How it makes money
Today almost every dollar comes from seasonal vaccines sold each autumn, mostly COVID shots, so sales swing by quarter: $1.31B in the third quarter of 2026, but $2.53B over twelve months against a loss of $2.93B. If the cancer vaccine is approved, Moderna makes it and Merck shares the selling, and the two split the costs and any profit equally.
The evidence under this - 4 claims
One quarter: the COVID season is concentrated in the third and fourth quarters, and the nine-month result is still a large loss.
Where the money comes from, stream by stream
| Stream | Share of sales (2025) | How it earns it |
|---|---|---|
| COVID-19 vaccines (Spikevax, mNEXSPIKE) | 93% | Seasonal shots sold to governments, pharmacies and health systems, mostly in the autumn. |
| RSV vaccine (mRESVIA) | under 1% | A vaccine for older adults, launched in 2024 after GSK's and Pfizer's. |
| Other revenue | about 7% | Grants, collaboration revenue and fees for keeping plants ready for governments. |
Who runs it
Stéphane Bancel has run Moderna since 2011 and owns 7.6% of the shares; co-founder and chairman Noubar Afeyan owns 1.8%. A new chief operating officer, Juan Andres, returned in October 2026 to run manufacturing for the launch.
Bancel's bonus paid 170% of target in 2025, while his share awards tied to results vested at about half. Insiders bought no shares in the past year and sold 1,073,172, nearly all under plans set in advance.
The evidence under this - 3 claims
Why it wins, and who could beat it
Why customers come back
In vaccines there is little to keep a buyer: governments and pharmacies switch on price and data each season.
The cancer vaccine is different. It is the only personalised vaccine with a positive late-stage trial, and BioNTech's version stopped its bowel cancer trial. A US biologic gets 12 years of protection from copies, and a rival needs its own large trial in each cancer. That lead is real, but it has not yet earned a dollar.
The evidence under this - 3 claims
Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.
The threat
Pfizer and BioNTech sell the larger COVID vaccine, and Comirnaty's sales are shrinking too. Novavax sells a protein-based shot through Sanofi, and GSK and Pfizer reached the RSV market first. In cancer the closest rival is BioNTech's own personalised vaccine, which failed in bowel cancer.
The evidence under this - 4 claims
The rivals: PFE, BNTX, NVAX, SNY, GSK, MRK.
Who else does this, rival by rival
| Ticker | Rival | Where it competes | How far along | Priced against it |
|---|---|---|---|---|
| PFE · BNTX | Pfizer and BioNTech's ComirnatyPriced against it: Yes | Respiratory vaccines: COVID, RSV and flu | On sale | Yes |
| NVAX · SNY | Novavax's Nuvaxovid, sold by Sanofi, and Sanofi's flu vaccinesPriced against it: Yes | Respiratory vaccines: COVID, RSV and flu | On sale | Yes |
| GSK · PFE | GSK's Arexvy and Pfizer's Abrysvo against RSVPriced against it: One segment only | Respiratory vaccines: COVID, RSV and flu | On sale | One segment only |
| BNTX | BioNTech's autogene cevumeran, its own individualized mRNA cancer vaccinePriced against it: Yes | Cancer and rare-disease medicines in development | In research | Yes |
| MRK | Merck's Keytruda alone after surgeryPriced against it: Not checked | Cancer and rare-disease medicines in development | On sale | Not checked |
How big it could get
How big this could get
About 112,000 Americans will be found with melanoma in 2026, and roughly 11,000 of them with cancer that has reached nearby lymph nodes, the kind the trial treated. A year of Keytruda lists at about $217,000, so melanoma alone could be about $2.4B a year in the US at full use, before Merck takes its half. Lung cancer, if its trial works, would be far larger.
The evidence under this - 4 claims
The trial's eligible group is not exactly the regional stage, and Moderna keeps only half of any profit (C11).
List price is not what payers pay after discounts, and intismeran's own price is not set.
Who has signed
Merck has signed to share the cancer vaccine's costs and profits equally worldwide. Canada, the United Kingdom and Australia have long-term vaccine partnerships with plants built on their soil, and Recordati licensed a rare-disease medicine for $50M upfront.
The evidence under this - 3 claims
The results
The numbers
Sales grew 13% over the twelve months to Sep 2026, faster than the −40% in the year to Dec 2025.
Operating margin is −116%, down from −62% in the year to Dec 2023.
Running costs take 144¢ of each sales dollar, up from 14¢ in the year to Dec 2021.
Shareholders' money lost 35% a year, down from 146% in the year to Dec 2021.
It used $1.97B of cash over the last twelve months, so the $5.17B it holds lasts about 2.6 years at that pace.
It holds $5.17B of cash against $3.55B of debt, $1.62B more cash than it owes.
The share count barely moved in 4.8 years, and pay in shares costs 18% of sales.
All the numbers
Filed figures from the company's 10-K and 10-Q, read 2026-11-17. Fiscal years end in December.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | 12 mo to Sep 2026 | |
|---|---|---|---|---|---|---|
| Size and growth | ||||||
| Sales | $18.5B | $19.3B | $6.85B | $3.24B | $1.94B | $2.52B |
| Sales growth | +22× | +4.3% | −64% | −53% | −40% | +13% |
| Profit | ||||||
| Gross margin | 86% | 72% | 31% | 55% | 55% | 28% |
| Operating margin | 72% | 49% | −62% | −122% | −158% | −116% |
| Net margin | 66% | 43% | −69% | −110% | −145% | −110% |
| What growth costs, per sales dollar | ||||||
| Research and development | 11% | 17% | 71% | 140% | 161% | 105% |
| General and admin | 3.1% | 5.9% | 23% | 36% | 52% | - |
| Pay in shares | 0.8% | 1.2% | 4.5% | 13% | 25% | 18% |
| Capital spending | 1.5% | 2.1% | 10% | 32% | 9.9% | 7.3% |
| Cash | ||||||
| Cash from operations | $13.6B | $4.98B | −$3.12B | −$3.00B | −$1.87B | −$1.78B |
| Free cash flow | $13.3B | $4.58B | −$3.83B | −$4.05B | −$2.06B | −$1.97B |
| Balance sheet | ||||||
| Cash and short-term investments | $10.7B | $9.90B | $8.60B | $7.03B | $5.80B | $5.17B |
| Debt | - | - | - | $0 | $590M | $3.55B |
| Net cash | - | - | - | $7.03B | $5.21B | $1.62B |
| Returns and shares | ||||||
| Return on capital | 146% | 49% | - | - | - | - |
| Shares (diluted) | 431M | 416M | 382M | 384M | 389M | 430M |
What growth costs
There has been no growth to pay for: sales fell nine-tenths in three years. Moderna cut research from $4.5B in 2024 to $3.1B in 2025 and building spending almost to nothing, and plans about $2.7B of research this year. The loss is shrinking because costs fall, not because sales rise.
The evidence under this - 3 claims
Revenue guidance has been cut repeatedly since 2023; this one was raised only after a strong third quarter.
The last report (6 Nov)
Quarter ended September 2026, filed figures.
In the quarter to September 2026 sales rose 29% to $1.31B and Moderna earned $162M, helped by European sales of $314M against $16M a year earlier. Research spending fell 27%.
Management now expects 2026 sales to grow 15% to 25%, up from up to 10% in January, and year-end cash of $8.1B to $8.3B. Nine months still used $2.72B of cash, including the $950M patent settlement.
What it did to the thesisIt helped the vaccine business: sales grew again and costs kept falling. It left the case where it was, because the price rests on the cancer vaccine, which the quarter did not test, and the business still loses money over the year.
The quarter in detail
Sales growth from the previous quarter, filed figures. The company has restated its own history, so a quarter either side of the restatement may describe a different business; n/c marks one that does not compare.
Earnings per share $0.38 against $-1.10 expected; $0.38 as filed, with no adjustments.
The evidence under this - 4 claims
One quarter: the COVID season is concentrated in the third and fourth quarters, and the nine-month result is still a large loss.
Revenue guidance has been cut repeatedly since 2023; this one was raised only after a strong third quarter.
What management did with the money
Insiders in 2026Q3: 25 purchases and 42 sales, from their Form 4 filings.
The price, and where we disagree
In short. Priced for perfection. The price pays for the cancer vaccine succeeding in several common cancers, and is above even our optimistic value.
The shares nearly tripled on 19 August, the day the melanoma trial succeeded, fell about a sixth on 22 October when the full data leaked early, and slipped after the 12 November analyst day.
Moderna plans to ask for US approval by the end of 2026 and to launch with Merck in 2027. The next tests are the fourth-quarter report in February and a kidney cancer trial reading around the turn of the year.
The evidence under this - 4 claims
A filing is not an approval, and an individualized medicine made for each patient has no precedent at this scale.
Enrolment says nothing about results; the closest rival's personalised vaccine failed in another tumour (C14).
How we value it
- Method
- Cash the business will produce, with any shortfall raised in new shares
- Required return
- 8%
- Long-run growth
- 4%
- Moat
- No moat
| Bear | Base | Bull | |
|---|---|---|---|
| Sales growth, years 1 to 3 | 0.4%, 16.6%, 28% | 0.8%, 33.2%, 55.9% | 1%, 41.5%, 69.9% |
| Normal operating margin | 16.1% | 20.2% | 22.2% |
| Return on new capital after year ten | 8% | 8% | 11% |
| Value a share | $16.70 | $38.97 | $78.13 |
- Price
- $215
- Priced on
- 16 Nov
- Price as a share of the base value
- 552%
- Yearly return the price offers on the base case
- 4.9%
- Risk check: valued at 12%, the rate for a business not yet making a profit
- $22.31
Where each figure comes from
| Figure | Source | Where exactly |
|---|---|---|
| Sales, the last twelve months | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the four quarters to that date. |
| Operating margin today | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the four quarters to that date. |
| Tax rate | Our method's rule | The normal rate where no rate is filed to read: 25% for a US company, 21% elsewhere. |
| Sales per dollar of new capital | Filed report | Annual report (10-K) for the period to 31 Dec 2025, filed 20 Feb 2026: the year's sales over its operating capital. |
| Shares | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the diluted share count. |
| Cash and investments | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the balance sheet on that date. |
| Debt | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the balance sheet on that date. |
| Sales growth, years 1 to 3 | Analysts' forecasts | FMP's consensus for the years to 31 Dec 2026, 31 Dec 2027, 31 Dec 2028 and 31 Dec 2029: the average of 13 to 17 analysts' revenue estimates, 0.8%, 33.2%, 55.9%. FMP publishes how many analysts, not who they are. |
| Normal operating margin | Analysts' forecasts | FMP's consensus operating margin for the year to 31 Dec 2030, the average of 8 analysts' estimates, 26.2%, less stock pay of 6% of sales. FMP publishes how many analysts, not who they are. |
| Return on new capital after year ten | Our method's rule | Set by our reading of the moat: the 8% rate with none, 12% with an average one, 15% with a strong one; the bear case earns the rate. |
| The bear and bull cases | Our method's rule | Our method's spread: the bear case takes half the growth and a fifth off the margin, the bull a quarter more growth and a tenth more margin. |
| Price | Market price | FMP's closing price on 16 Nov 2026. |
| Other investments | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 6 Nov 2026; the balance sheet on that date. |
What each case rests on
Bear caseGrowth runs at half the analysts' path, 0.4%, 16.6% and 28.0%, the margin settles a fifth lower at 16.1%, and new capital earns only the 8% rate: intismeran's launch slow and the vaccines still shrinking.
Base caseRevenue grows 0.8%, 33.2% and 55.9% over three years, the analysts' path (C26) that already carries intismeran's launch, then fades toward 4%, closing 30% of the gap each year; the margin moves to 20.2%, the analysts' 2030 figure after stock pay, which is 18.4% of sales today and fades to a mature 6%.
Bull caseGrowth runs a quarter above the analysts' path, 1.0%, 41.5% and 69.9%, as lung cancer and other tumours follow melanoma, the margin reaches 22.2%, and new capital earns 11%.
What moves the base value
| Lower | Higher | |
|---|---|---|
| Growth in years 1 to 3, a quarter lower or higher | $28.83 | $53.45 |
| The normal margin, 15% lower or higher | $33.00 | $45.29 |
| Capital per dollar of growth, a quarter more or less | $38.16 | $39.91 |
| Return on new capital after year ten, at the rate or one step up | $38.97 | $51.70 |
| The rate, a point higher or lower | $29.22 | $55.71 |
| Long-run growth a point lower | $38.03 | - |
Value a share as growth and margin change
| Normal margin ↓ · growth → | 50% | 75% | 100% | 125% | 150% |
|---|---|---|---|---|---|
| 16.2% | $16.75 | $22.79 | $31.04 | $42.64 | $56.80 |
| 18.2% | $18.86 | $25.81 | $34.98 | $48.02 | $63.87 |
| 20.2% | $20.98 | $28.83 | $38.97 | $53.45 | $70.98 |
| 22.2% | $23.09 | $31.87 | $43.17 | $58.93 | $78.12 |
| 24.2% | $25.22 | $34.91 | $47.42 | $64.46 | $85.28 |
Growth is shown as a share of the base case's. Green: the price is at or under 80% of that value. Red: at or over 120%.
How we read the multiple
Moderna has no profit to price, so we value it on the analysts' sales path, which already includes the cancer vaccine's launch, counting stock pay as a cost and requiring an 8% yearly return.
The analysts expect sales of $8.22B in 2030, against about $2.29B this year. Even then the business is worth about $39 a share, and about $78 in our optimistic case, against a price of $215.
Against its own history. Far above anything it has fetched since the pandemic; the gap is the price of a cancer vaccine that has not yet sold.
The evidence under this - 4 claims
The analysts' path may undercount intismeran in lung and other cancers; the bull case is the check, and the price is still nearly three times it.
A rival with a proven cancer platform could be worth this; the price could be pricing a platform beyond intismeran.
Nine analysts forecast 2029 and fewer 2030; the jump in 2029 rests on intismeran sales nobody has yet seen.
Both peers sell mostly COVID vaccines and price little for oncology, so the gap measures the cancer pipeline as much as the vaccine business.
Priced against its rivals
The competitors its own annual report names, each confirmed against the rival's filing. Measured on company value for each $1 of sales, cheapest first:
| Ticker | Company | company value for each $1 of sales |
|---|---|---|
| NVAX | Novavax | 2.4× |
| BNTX | BioNTech SE | 3.9× |
| MRNA | Moderna | 33.0× |
The middle of the other 2 is 3.1. Moderna, Inc. is dearest of 3.
Rivals' figures come from a data provider, so read the spread of the group rather than any single pair.
Many times its filed vaccine rivals, which price their shots and little else; the gap is Moderna's own, the cancer vaccine.
The bet: what it pays if it works
This bet is on the cancer vaccine and the rare-disease medicines. It works if the vaccine is approved, launched with Merck and then spreads beyond melanoma.
Even a large win in melanoma, with Moderna's half of the profit, would be worth only a fraction of today's company value. If it fails, shareholders keep a shrinking vaccine business worth a small part of the price, so the bet is priced and expensive.
| Cancer and rare-disease medicines in development revenue in two to three years | Patient-years at a year of Keytruda's list price needed | At the stated multiple |
|---|---|---|
| $300.00M | about 2.8K at 50% kept | 0.1× |
| $1.00B (the big win) | about 9.2K at 50% kept | 0.2× |
| $2.50B | about 23.0K at 50% kept | 0.3× |
To pay 2× (a Fair bet) it would need about $20.03B of Cancer and rare-disease medicines in development revenue (about 184.6K patient-years at a year of Keytruda's list price at 50% kept); to pay 5× (a Cheap bet), about $51.27B of Cancer and rare-disease medicines in development revenue (about 472.6K patient-years at a year of Keytruda's list price at 50% kept), at the same multiple.
Each row is Cancer and rare-disease medicines in development alone, plus the rest of the company (Respiratory vaccines: COVID, RSV and flu) counted at about $6.34B.
The steps it has to take
- Done Phase 3 in melanoma meets its main goal
- In progress US approval filing for intismeran in melanoma due 2026-12
- In progress Kidney cancer Phase 2 reads out due 2027-03
- Not started US approval and launch in melanoma with Merck due 2027-12
- In progress Lung cancer Phase 3 reports its first analysis due 2028-12
The detail behind the label
The evidence under this - 6 claims
Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.
A filing is not an approval, and an individualized medicine made for each patient has no precedent at this scale.
List price is not what payers pay after discounts, and intismeran's own price is not set.
Both peers sell mostly COVID vaccines and price little for oncology, so the gap measures the cancer pipeline as much as the vaccine business.
Where we disagree with the market
The cancer vaccine works, so Moderna is now a cancer company with a technology worth paying up for.
The melanoma result is real, but Merck takes half the profit and the vaccines keep shrinking, so even our optimistic value sits far below the price.
The market has priced the technology as proven in many cancers. It has worked in one, the survival benefit is not yet shown, and a rival's version failed in another.
The evidence against us: if the lung cancer trial succeeds and the launch is priced near a year of Keytruda, the vaccine could be far bigger than the analysts expect.
What analysts say, and the evidence
The evidence under this - 6 claims
Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.
The analysts' path may undercount intismeran in lung and other cancers; the bull case is the check, and the price is still nearly three times it.
What could go wrong, and how we would know
The risks
- Survival not yet shown. The trial proved fewer cancers came back; if lives are not lengthened, insurers may refuse to pay on top of Keytruda.
- One medicine carries the price. A miss in lung cancer, or a rival's failure repeating in another tumour, would remove most of what the shares pay for.
- Shrinking vaccines. Only about one adult in six took last season's COVID shot, and sales keep falling across the industry.
- Making a medicine per patient. Each dose is built from one tumour; slow or costly manufacturing could limit how many patients are treated.
- Patents cut both ways. Moderna paid $950M to settle one suit, lost a European patent this year and still sues Pfizer and BioNTech.
The evidence under this - 6 claims
Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.
The $3.0B of convertibles count in liquidity but are debt, due in 2032.
A filing is not an approval, and an individualized medicine made for each patient has no precedent at this scale.
What we still do not know
- What the cancer vaccine will cost, and whether Medicare will pay for it on top of Keytruda.
- Whether fewer cancers coming back turns into longer lives in the melanoma trial.
- Whether Moderna can make each patient's dose in about six weeks at commercial scale.
The evidence under this - 3 claims
A filing is not an approval, and an individualized medicine made for each patient has no precedent at this scale.
Overall survival is not yet shown, and the trial compares against Keytruda alone, not against other add-on treatments.
Enrolment says nothing about results; the closest rival's personalised vaccine failed in another tumour (C14).
What would change our view
- Unattractive→NeutralThe price falls back within 20% of fair value
It needs:
- ○The share price falls back within 20% of what we think the business is worth.about ≈$38.30 today, 82% below the last close
- Unattractive→AttractiveThe price falls 20% under fair value
It needs:
- ○The share price falls to 80% of what we think the business is worth.about ≈$21.96 today, 90% below the last close
- Unattractive→NeutralIntismeran proves itself beyond melanoma
It needs all of:
- ○The lung cancer trial reports a clear cut in cancers coming back at its first look.watched as it happens
- ○The US approves the vaccine for melanoma at a price near a year of Keytruda.watched as it happens
We would also be wrong if
- COVID, RSV and flu vaccine sales grow again in 2027, with more than a fifth of US adults taking a COVID shot.
What is coming
- 12 February 2027 Q4 2026 results and the intismeran filing: Whether the FDA filing went in, whether 2026 revenue landed in the guide and what 2027 spending looks like.
Every dated event ahead
- 12 February 2027 Q4 2026 results and the intismeran filing: Whether the FDA filing went in, whether 2026 revenue landed in the guide and what 2027 spending looks like.
- 31 March 2027 Kidney cancer Phase 2 readout for intismeran: The first test of the vaccine outside melanoma.
- 31 December 2027 FDA decision on intismeran in melanoma: Whether it can be sold, at what price, and how fast each dose can be made.
Since we wrote this
- 17 NovThesis writtenUnattractive, high convictionThe cancer vaccine works in melanoma, but half the profit is Merck's and the price sits far above even our bull case.
Sources 23
Sources - 23
Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.
- S01primarycompany filing2026-02-20products, the Merck collaboration, competition, government partnerships, data exclusivity, employees, risk factors and the statementsbacksC01C02C03C05C11C22C32C33C34C37C38C39
- S02primarycompany filing2026-11-06Q3 revenue by product and region, profit, the 2026 outlook, approvals and pipeline updatesbacksC01C04C06C10C36C43C46
- S03primarycompany filing2026-11-06the balance sheet, the convertible notes, the Arbutus, GSK and Pfizer litigation, the Recordati licence and the nine-month cash flowbacksC04C05C07C08C22C30C31C34C36C44
- S04primarytranscript2026-11-06Third quarter 2026 earnings call transcript (FMP), held 2026-11-06data/cache/transcripts/MRNA-2026Q3.jsonmanagement on the oncology trials, the respiratory season, costs and the intismeran launch
In non small cell lung cancer, the adjuvant Phase 3 study is fully enrolled.
backsC13 - S05primarycompany filing2026-03-16share ownership of officers, directors and large holders, and how executives are paidbacksC27C28
- S06primarycompany filing2026-09-01the notes' size, coupon, maturity, conversion price and capped callbacksC08
- S07primarycompany filing2026-11-16the lower interest margin, the later maturity and the delayed-draw loansbacksC09C43
- S08primarycompany filing2026-09-30the new chief operating officer, the retirement of the head of technical operations and five approved vaccinesbacksC01
- S09primarycompany filing2026-11-13the legal chief's retirement on 31 March 2027read, but no claim rests on it
- S10secondarynews2026-10-26The ASCO Post: personalized mRNA vaccine plus immunotherapy reduces risk of recurrence after surgery (INTerpath-001) The ASCO Post (American Society of Clinical Oncology)the Phase 3 melanoma results as presented: patients, hazard ratio, two-year rates and immature survival data
At 2 years, 82.2% of patients receiving the combination were alive without recurrence
backsC10 - S11primarygovernment data2026-04-01National Cancer Institute SEER, Cancer Stat Facts: Melanoma of the Skin National Cancer Institute (SEER)US melanoma cases and deaths expected in 2026, and the share diagnosed at each stage
there will be 112,000 new cases of melanoma of the skin and an estimated 8,510 people will die of this disease
backsC15C42 - S12primarycompany release2026-09-01Merck, KEYTRUDA cost and financial support page Merck & Co.the list price of the medicine intismeran is given with, current as of September 2026
The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $12,517.44.
backsC16C41C42 - S13secondarynews2026-08-31BioPharm International: BioNTech halts Phase 2 trial of individualized mRNA cancer vaccine autogene cevumeran in colorectal cancer BioPharm Internationalthat the closest rival individualized cancer vaccine stopped its colorectal trial on a survival imbalance
BioNTech announced it has terminated the Phase 2 BNT122-01 trial
backsC14 - S14secondarynews2026-11-12the analyst day: filing and launch timing, Merck's role, 2027 spending, liquidity, the VA study and flu vaccine reach
Moderna expects approximately $4 billion in companywide investment in 2027
backsC12C35C43 - S15primarygovernment data2026-02-22CDC COVIDVaxView: adult vaccination coverage, 2025-26 season US Centers for Disease Control and Preventionthe share of US adults who took a COVID-19 vaccine in the 2025-26 season: 17.5% as of 22 February 2026
of adults reported having received the 2025─26 COVID-19 vaccine.
backsC17 - S16primarycompany filing2026-11-05Comirnaty and Abrysvo revenue in the quarter and nine months against a year earlierbacksC18
- S17primarycompany filing2026-03-10BioNTech Form 20-F for 2025 BioNTechBioNTech's COVID-19 vaccine revenue against its total, and its own individualized cancer vaccine programmebacksC19
- S18primarycompany filing2026-02-26Novavax Form 10-K for 2025 Novavaxthat its protein-based COVID-19 vaccine is now sold through SanofibacksC20
- S19secondaryvendor data2026-11-17Research pack frozen beside this thesis, 2026-11-17content/MRNA/research-pack.jsonthe 16 November close, returns and their decomposition, the cohort, the rating split and its history, target drift, short interest and insider tradesbacksC03C21C22C23C24C25C29C32C44C45
- S20secondaryvendor data2026-11-17the analysts' average revenue, earnings and operating profit for 2026 to 2030, and how many analysts are behind each yearbacksC26C44C45
- S21primarycompany filing2026-11-09each open-market sale, its price and whether it was made under a Rule 10b5-1 planbacksC29
- S22secondaryvendor data2026-11-17the closes either side of the melanoma readout, the early leak of the full data and the analyst daybacksC40
- S23primarycompany filing2026-01-122025 revenue of about $1.9B, about $2B of yearly cost cuts, and the first 2026 guide of up to 10% growthbacksC46